Staff Investigator - Turkson

夏威夷癌症中心请求为两（2）名研究人员提供部分支持，他们将专注于癌症中心主要关注的战略研究/临床领域。 James Turkson博士，最近从Moffit癌症中心和中央佛罗里达大学招募到夏威夷癌症中心大学，将领导在癌症生物学计划内创建一个强大的药物开发计划，目标是建立科学合作，重点是涉及基础科学计划和我们的临床合作伙伴的癌症中心成员的转化研究。Turkson博士在药物开发方面拥有丰富的经验，已经花了十多年的时间设计和评估信号转导和转录激活因子-3（STAT-3）蛋白的小分子抑制剂。STAT-3介导多种基因响应细胞刺激的表达，并在许多细胞过程中发挥关键作用，包括各种人类癌症的起始和进展。Turkson博士在该领域发表了50多篇同行评审论文，并与他人合著了4项已授权专利和8项临时和待审专利。

The University of Hawaii Cancer Center is requesting partial support for two (2) Staff Investigators, each of whom will focus on a strategic research/clinical area of major interest to the Cancer Center. James Turkson, PhD, a recent recruit to the University of Hawaii Cancer Center from the Moffit Cancer Center and the University of Central Florida, will lead the creation of a robust drug development initiative within the Cancer Biology Program with the goal of building scientific collaborations focused on translational research involving Cancer Center members from both the basic science programs and our clinical partners. Dr. Turkson has extensive experience in drug development having spent more than a decade designing and evaluating small molecule inhibitors of the signaling transducer and activator of transcription-3 (STAT-3) protein. STAT-3 mediates the expression of a variety of genes in response to cell stimuli and plays a key role in many cellular processes, including the initiation and progression of various human cancers. Dr. Turkson has published over 50 peer reviewed papers and co-authored 4 issued patents and 8 provisional and pending patents in the field.